Kevin Hern | Vice President of Investor Relations |
David Ricks | Chairman and Chief Executive Officer |
Anat Ashkenazi | Chief Financial Officer |
Daniel Skovronsky | Chief Scientific and Medical Officer |
Anne White | President of Lilly Neuroscience |
Ilya Yuffa | President of Lilly International |
Jake Van Naarden | CEO of Loxo Oncology at Lilly and President of Lilly Oncology |
Michael Mason | President of Lilly Diabetes |
Patrik Jonsson | President of Lilly Immunology and Lilly U.S.A. |
Lauren Zierke | Investor Relations team |
KentoUeha | Investor Relations team |
Sara Smith | Investor Relations team |
Seamus Fernandez | Guggenheim Securities |
Aaron Gal | Sanford C. Bernstein & Co., |
Vamil Divan | Mizuho Securities USA LLC |
Stephen Scala | Cowen and Company, LLC |
Christopher Schott | JPMorgan Chase & Co |
Alice Nettleton | Wolfe Research. |
Andrew Baum | Citigroup Inc. |
Geoffrey Meacham | BofA Securities |
Louise Chen | Cantor Fitzgerald & Co. |
Michael DiFiore | Evercore ISI Institutional Equities |
Carter Gould | Barclays Bank PLC |
Kerry Holford | Joh. Berenberg, Gossler& Co. KG |
Chris Shibutani | Goldman Sachs Group, Inc., |
Ladies and gentlemen, thank you for standing by, and welcome to the Eli Lilly Q4 2021 Earnings Call. [Operator Instructions] As a reminder, today’s conference is being recorded. I would now like to turn the conference over to Vice President of Investor Relations, Kevin Hern. Please go ahead.
Good morning.